The consequences of extended newborn screening programmes: Do we know who needs treatment?
- 169 Downloads
The development of an evidence base for newborn screening is especially difficult because of the rarity of disorders now detectable. One consequence of expanded newborn screening is that physicians are being called upon to manage asymptomatic babies with persistent biochemical disturbances that indicate likely enzyme deficiencies. Some of these may be very mild. There is not always agreement as to who should be treated. Particular problems are seen with disorders that were previously thought very rare but are now found frequently by newborn screening. Some of these disorders appear benign or nearly so, and in the present state of knowledge should clearly not be included in routine newborn screening panels.
medium-chain acyl-CoA dehydrogenase
- Andresen BS, Dobrowolski SF, O’Reilly L, et al (2001) Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68: 1408–1418.PubMedCrossRefGoogle Scholar
- Arnold GL, Koeberl DD, Matern D, et al (2008) A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab [In press].Google Scholar
- Seymour CA, Thomason MJ, Chalmers RA, et al (2001) Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1: 23–26.Google Scholar
- Tuchman M, Berry SA, Thuy LP, Nyhan WL (2007) Partial methylcroyonyl-coenzyme A carboxylase deficiency in an infant with failure to thrive, gastrointestinal dysfunction, and hypertonia. Pediatrics 1993: 664–666.Google Scholar
- Wilson JMG, Jungner G (1968) Principles and Practice of Screening for Disease, Geneva: World Health Organization.Google Scholar